Biosimilars and Monoclonal Antibodies: Key Segments Driving China's Multi-Billion Dollar Biologics Expansion
Monoclonal antibodies (MAbs) and biosimilars represent the twin engines of growth within the rapidly expanding **China Biologics Market**, collectively driving its valuation into the multi-billion dollar range. MAbs, which target specific antigens and offer unparalleled precision in treatment, are indispensable for complex disease management, particularly in oncology and chronic inflammatory...
0 Commentaires 0 Parts 10 Vue 0 Aperçu